A Bioequivalence Study of Hetrombopag in Healthy Subjects
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This study consists of two parts. Part 1 is a pilot BE study, and Part 2 is a pivotal study
to demonstrate the bioequivalence of test and reference formulation, both of which adopt a
single-center, randomized, open-label, three-period crossover design.